HLB's liver cancer drug FDA approval this year reportedly in doubt

Reports suggest HLB's liver cancer drug (ivonescimab) FDA approval is unlikely to come this year, despite earlier confidence in a Class 1 review. The PDUFA action date is set for November 14, 2026.

Detected & updated continuously · Source: Nebula